PT1622908E - Derivados de xantina como antagonistas do receptor a2b de adenosina - Google Patents

Derivados de xantina como antagonistas do receptor a2b de adenosina Download PDF

Info

Publication number
PT1622908E
PT1622908E PT03817096T PT03817096T PT1622908E PT 1622908 E PT1622908 E PT 1622908E PT 03817096 T PT03817096 T PT 03817096T PT 03817096 T PT03817096 T PT 03817096T PT 1622908 E PT1622908 E PT 1622908E
Authority
PT
Portugal
Prior art keywords
receptor antagonists
adenosine receptor
xanthine derivatives
xanthine
derivatives
Prior art date
Application number
PT03817096T
Other languages
English (en)
Portuguese (pt)
Inventor
Prabha Ibrahim
Elfatih Elzein
Venkata Palle
Jeff Zablocki
Dengming Xiao
Rao Kalla
Thao Perry
Xiaofen Li
Vaibhav Varkhedkar
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of PT1622908E publication Critical patent/PT1622908E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PT03817096T 2003-05-06 2003-05-06 Derivados de xantina como antagonistas do receptor a2b de adenosina PT1622908E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/014085 WO2004106337A1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
PT1622908E true PT1622908E (pt) 2008-11-14

Family

ID=33488737

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03817096T PT1622908E (pt) 2003-05-06 2003-05-06 Derivados de xantina como antagonistas do receptor a2b de adenosina

Country Status (15)

Country Link
EP (1) EP1622908B1 (enExample)
JP (1) JP2006515316A (enExample)
CN (1) CN100590125C (enExample)
AT (1) ATE403656T1 (enExample)
AU (1) AU2003249604B2 (enExample)
CA (1) CA2524778C (enExample)
CY (1) CY1108457T1 (enExample)
DE (1) DE60322748D1 (enExample)
DK (1) DK1622908T3 (enExample)
ES (1) ES2311759T3 (enExample)
MX (1) MXPA05011860A (enExample)
NZ (1) NZ543416A (enExample)
PT (1) PT1622908E (enExample)
SI (1) SI1622908T1 (enExample)
WO (1) WO2004106337A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
EP2970303B3 (en) * 2013-03-15 2018-08-01 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
US11045472B2 (en) * 2017-05-05 2021-06-29 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
US20210040097A1 (en) * 2018-03-05 2021-02-11 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
CN118459463B (zh) * 2024-07-10 2024-09-06 山东中医药大学附属医院 一种化合物及其制备方法和治疗2型糖尿病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4878296A (en) * 1988-04-22 1989-11-07 The United States Of America As Represented By The Secretary Of The Navy Apparatus and method for locating the axis of symmetry (center of circular cross section) of three dimensional objects
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
ES2189079T3 (es) * 1998-04-24 2003-07-01 Leuven K U Res & Dev Efectos inmunosupresores de derivados de xantina 8-sustituidos.
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
KR100883292B1 (ko) * 2001-06-29 2009-02-11 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체
PT1444233E (pt) * 2001-11-09 2011-09-29 Gilead Palo Alto Inc Antagonistas de receptor de adenosina a2b
WO2003063800A2 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Also Published As

Publication number Publication date
NZ543416A (en) 2009-01-31
EP1622908A1 (en) 2006-02-08
HK1092137A1 (en) 2007-02-02
DE60322748D1 (de) 2008-09-18
AU2003249604B2 (en) 2011-06-30
MXPA05011860A (es) 2006-02-17
JP2006515316A (ja) 2006-05-25
CN100590125C (zh) 2010-02-17
EP1622908B1 (en) 2008-08-06
ATE403656T1 (de) 2008-08-15
AU2003249604A1 (en) 2005-01-21
SI1622908T1 (sl) 2008-12-31
CN1771250A (zh) 2006-05-10
DK1622908T3 (da) 2008-11-17
ES2311759T3 (es) 2009-02-16
CA2524778A1 (en) 2004-12-09
WO2004106337A1 (en) 2004-12-09
CA2524778C (en) 2013-01-29
CY1108457T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
SI1622908T1 (sl) Ksantinski derivati kot antagonisti A2B adenozinskega receptorja
WO2003042214A3 (en) A2b adenosine receptor antagonists
MXPA03008967A (es) Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
ZA200705040B (en) 2,4 (4,6) pyrimidine derivatives
TWI349672B (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
SI3184526T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
IL165046A0 (en) Pyrimidinone compounds, compositions and methods
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
WO2005105803A3 (en) Purine derivatives as a1 adenosine receptor antagonists
IL172899A0 (en) Heterocyclically substituted pentanol derivatives, method for the production thereof, and use thereof as anti-inflammatory agents
SI1622912T1 (sl) 2-alkinil- in 2-alkenil-pirazolo-(4,3-E)-1,2,4-triazolo-(1,5-C)-pirimidin adenozinski A2a receptorski antagonisti
PT1608653E (pt) Derivados substituídos de 8-perfluoroalquil-6,7,8,9-tetrahidropirimidino ( 1,2-a)pirimidin-4-ona
IL174771A0 (en) Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
MY129445A (en) Compositions for treating inflammatory response
IL164606A0 (en) Novel compounds
SI1534707T1 (sl) Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
TNSN05133A1 (en) Imidazoquinoline derivatives as adenosine a3 receptor ligands
WO2008027585A3 (en) Pyrrolo[3,2-d]pyrimidines that are selective antagonists of a2b adenosine receptors
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
PL378983A1 (pl) Pochodne ksantyny jako antagoniści receptora adenozyny A2B
AU2003261206A8 (en) Xanthine derivatives having adenosine a1-receptor antagonist properties